Global Health Page
Certara Global Health (CGH) brings together talent, technology, and software to accelerate the development of medicines for those that need them most.
Upcoming Simcyp Workshops Page
Enhance your drug development skills with Certara’s Simcyp PBPK workshops. View our upcoming workshops.
Payment Page
Rare and Neglected Diseases Page
运用我们久经验证的生物模拟软件与专业洞见，攻克罕见病药物研发难题，自 2014 年以来，Certara 为 90% FDA 孤儿药的审批提供了支持。
Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology Publication
Bispecific antibodies (bsAbs) have become an integral component of the therapeutic research strategy to treat cancer. In addition to clinically validated immune cell re‐targeting, bsAbs are being designed for tumor targeting and as dual immune modulators. Explorative preclinical and emerging...
The Research to Accelerate Cures and Equity (RACE) for Children Act: Changing the Landscape of Pediatric Cancer Drug Development Blog Post
3 key tips to set your pediatric program up for success with the RACE for Children Act by Lynne Georgopoulos, RN, MSHS, RAC, Vice President, Regulatory Strategy at Certara On 2020 年 8 月 18 日, the Research to Accelerate Cures and Equity...
Salvaging CNS Clinical Trials Halted Due to COVID‐19 Publication
The coronavirus disease 2019 (COVID‐19) pandemic has halted many ongoing central nervous system (CNS) clinical trials, especially in Alzheimer’s disease. These long‐duration trials involve many stakeholders, especially the patients and their family members, who have demonstrated their commitment to developing...
Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond Publication
Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly binds to the active site of FXa, and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin. Apixaban is approved in...
